SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the J apanese M usculoskeletal O ncology G roup
…, K Ida, S Kimura, M Murase, M Kano, M Emori… - Cancer …, 2012 - Wiley Online Library
In the present study, we evaluated the safety and effectiveness of SYT ‐ SSX ‐derived peptide
vaccines in patients with advanced synovial sarcoma. A 9‐mer peptide spanning the SYT …
vaccines in patients with advanced synovial sarcoma. A 9‐mer peptide spanning the SYT …
Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
…, S Iyama, H Ikeda, M Kobune, M Emori… - Thoracic …, 2019 - Wiley Online Library
SMARCA4‐deficient thoracic sarcoma (SMARCA4‐DTS) is a new clinical entity characterized
by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective …
by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective …
[HTML][HTML] High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and …
M Emori, T Tsukahara, M Murase, M Kano, K Murata… - PloS one, 2013 - journals.plos.org
Epithelioid sarcoma (ES) is a relatively rare, highly malignant soft tissue sarcoma. The mainstay
of treatment is resection or amputation. Currently other therapeutic options available for …
of treatment is resection or amputation. Currently other therapeutic options available for …
Hip morphology influences the pattern of articular cartilage damage
M Kaya, T Suzuki, M Emori… - Knee Surgery, Sports …, 2016 - Wiley Online Library
Purpose The aim of this study was to obtain data on chondral damage and compare the
damage patterns of various hip disorders. Methods Data were collected at 100 consecutive …
damage patterns of various hip disorders. Methods Data were collected at 100 consecutive …
[HTML][HTML] The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma
…, T Gokita, J Manabe, M Kaya, M Emori… - European Journal of …, 2020 - Elsevier
Purpose The role of chemotherapy (CT) and radiotherapy (RT) for management of extraskeletal
osteosarcoma (ESOS) remains controversial. We examined disease outcomes for ESOS …
osteosarcoma (ESOS) remains controversial. We examined disease outcomes for ESOS …
NUTM2A-CIC fusion small round cell sarcoma: a genetically distinct variant of CIC-rearranged sarcoma
…, T Aoyama, H Asanuma, W Mukai, N Hama, M Emori… - Human pathology, 2017 - Elsevier
CIC-rearranged sarcoma is a new entity of undifferentiated small round cell sarcoma
characterized by chimeric fusions with CIC rearrangement. We report a NUTM2A-CIC fusion …
characterized by chimeric fusions with CIC rearrangement. We report a NUTM2A-CIC fusion …
[HTML][HTML] Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics
…, T Kubo, H Asanuma, T Aoyama, M Emori… - Diagnostic …, 2016 - Springer
Background Pseudomyogenic hemangioendothelioma (PHE) is an unusual vascular tumor
of intermediate malignancy that rarely metastasizes and tends to arise in the lower limbs of …
of intermediate malignancy that rarely metastasizes and tends to arise in the lower limbs of …
A phase 1 trial of NY‐ESO‐1‐specific TCR‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of …
…, N Seo, H Hattori, K Takada, M Emori… - … Journal of Cancer, 2023 - Wiley Online Library
The efficacy of immune checkpoint inhibitors is limited in refractory solid tumors. T‐cell receptor
gene‐modified T (TCR‐T)‐cell therapy has attracted attention as a new immunotherapy …
gene‐modified T (TCR‐T)‐cell therapy has attracted attention as a new immunotherapy …
[HTML][HTML] Fibroblasts induce expression of FGF4 in ovarian cancer stem-like cells/cancer-initiating cells and upregulate their tumor initiation capacity
…, J Matsuzaki, K Ikeda, M Yamauchi, M Emori… - Laboratory …, 2014 - nature.com
Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are defined as a small
population of cells within cancer that contribute to cancer initiation and progression. Cancer-…
population of cells within cancer that contribute to cancer initiation and progression. Cancer-…
[HTML][HTML] Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 …
…, A Kawai, T Kunisada, T Kubo, M Emori… - World Journal of …, 2018 - Springer
Background Giant cell tumor of bone (GCTB) is an intermediate tumor known to be locally
aggressive, but rarely metastasizing. To plan a prospective study of GCTB, we performed a …
aggressive, but rarely metastasizing. To plan a prospective study of GCTB, we performed a …